PRECEDENT 2002

NCT00270400

1 Treatments

Studied treatment  nesiritide (0.015 or 0.03 microg/kg/min)

Control treatment  Dobutamine (> or =5 microg/kg/min)

Concomittant treatments  -

2 Patients

Patients  Symptomatic, Decompensated CHF

Inclusion criteria  -

Exclusion criteria  -

3 Methods

Blinding  open

Design  Parallel groups

Centers  multicentre

Geographical area  -

Sizes  -9/-9

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>amelioration of Dyspnea at 24 h</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30 day death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30-d HF rehospitalization</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>30-d death or HF hospitalization</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Amelioration of Dyspnea at 6 h</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause death</td>
<td>-9</td>
<td>-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References